# To Evaluate OBI-833/OBI-821 in Patients With Locally Advanced, Globo H-Positive Esophageal Cancer for Recurrence

> **NCT05376423** · PHASE2 · UNKNOWN · sponsor: **National Taiwan University Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Esophageal Cancer

## Interventions

- **BIOLOGICAL:** OBI-833/OBI-821

## Key facts

- **NCT ID:** NCT05376423
- **Lead sponsor:** National Taiwan University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-02
- **Primary completion:** 2024-12
- **Final completion:** 2025-06
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2023-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05376423

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05376423, "To Evaluate OBI-833/OBI-821 in Patients With Locally Advanced, Globo H-Positive Esophageal Cancer for Recurrence". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05376423. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*